BKBonggi Kim

Bonggi Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bonggi Kim has a total of 114 co-authors. Here are the top co-authors by number of shared publications:

  • Eunmi Choi

    Department of Drug Safety Information, Korea Institute of Drug Safety and Risk Management, Anyang, Korea

    4 shared publications
  • Bora Yeon

    Korea Institute of Drug Safety and Risk Management, Anyang, Korea

    3 shared publications
  • In Young Choi

    Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea

    3 shared publications
  • Inho Lee

    Data & AI Strategy Division, Soonchunhyang University Medical Center, Seoul, Korea

    3 shared publications
  • Jewon Seo

    Department of Medical Information, Chonnam National University Hospital, Gwangju, Korea

    3 shared publications
  • Myungsik Yoo

    Department of Drug Safety Information, Korea Institute of Drug Safety and Risk Management, Anyang, Korea

    3 shared publications

Latest Publications

  • Open Access

    Use of Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Acute Kidney Injury: A Retrospective Cohort Study

    by Yeji Lee, Eonji Na, Soo Jung Sohn, In Young Choi, Jeonguk Lim, Mi Hyoung Moon, Seonjeong Byun, Im Sun, Sungwoo Go, Jun Yong Lee, et al.

    Yeji Lee, Eonji Na, Soo Jung Sohn, In Young Choi, Jeonguk Lim, Mi Hyoung Moon, Seonjeong Byun, Im Sun, Sungwoo Go, Jun Yong Lee, Yeon Woong Chung, Young Yul Kim, Mi Jung Rho, Jiyun Jung, Sae-Hoon Kim, Kwangsoo Kim, Siyeon Yi, Jinsu Lee, Inho Lee, SeoHui Choe, Seojeong Shin, Dong Yoon Kang, Changyoung Kim, Dosang Cho, Da Woon Sim, Jewon Seo, Young-Gyun Seo, Ye-Seul Song, Yeesuk Kim, Joon-Sung Park, SunGeu Chae, Hyung Joon Joo and Bonggi Kim. Pharmacoepidemiology and Risk Management 2026;18:223-39. https://doi.org/10.56142/perm.26.0021

  • Open Access

    Real‐World Evidence on Short‐Term Weight Changes Following Methylphenidate Use in Pediatric Population: A Retrospective Study Using Common Data Model

    by Haeyoung Lee, Eun‐Gee Park, Hyeon‐Jong Yang, Young‐Gyun Seo, Dong Yoon Kang, Changyoung Kim, Da Woon Sim, Jewon Seo, Sae‐Hoon Kim, Dosang Cho, et al.

    In July 2025, the Food and Drug Administration (FDA) warned of significant weight loss among young children receiving stimulants for attention‐deficit hyperactivity disorder. However, real‐world evidence on the magnitude and prevalence of stimulant‐associated weight loss remains limited. This study evaluated short‐term weight changes after methylphenidate initiation among youth aged 3–18 years using the Medical record Observation and Assessment of drug safety Common Data Model (MOA CDM) in Korea. We conducted a retrospective study using electronic health record‐based MOA CDM data from January 2008 to December 2024. The cohort included individuals aged 3–18 years with at least one methylphenidate prescription and had available weight measurements. The index date was defined as the first prescription date. Individuals without weight data within 45 days before or 90 days after the index date were excluded. Outcomes included changes in body weight (kg) and weight percentile, and the proportion having a ≥ 10‐percentile decline. Weight percentiles were calculated using the 2017 Korean National Growth Charts for Children and Adolescents. A total of 2087 youths from 17 nationwide hospitals were included; 68.71% were male, and 58.12% were aged 6–10 years. Within 3 months, mean body weight decreased by −0.33 kg (95% confidence interval [CI], −0.44 to −0.22) and mean weight percentile decreased by −2.49 percentiles (95% CI, −2.83 to −2.15). Overall, 21.57% had a ≥ 10 percentile decline, with larger reductions among pre‐school‐aged children (28.57%). Our findings underscores the importance of growth monitoring during treatment initiation.

  • Open Access

    Use of Hydroxychloroquine and Occurrence of Cardiac Disease and Death in South Korea

    by Nayeong Son, Youjin Jang, Bora Yeon, Sun Mi Shin, Hyun Joo Jung, In Young Choi, Wona Choi, Dong-Jin Chang, Hyeon-Jong Yang, Inho Lee, et al.

    Nayeong Son, Youjin Jang, Bora Yeon, Sun Mi Shin, Hyun Joo Jung, In Young Choi, Wona Choi, Dong-Jin Chang, Hyeon-Jong Yang, Inho Lee, Yong-Gyun Seo and Bonggi Kim. Pharmacoepidemiology and Risk Management 2025;17:246-60. https://doi.org/10.56142/perm.25.0027

  • Open Access

    Hydrochlorothiazide Use and the Risk of Non-Melanoma Skin Cancer in Hypertensives: A Nested Case-Control Study

    by Bora Yeon, Ah Young Suh, Eunmi Choi, Bonggi Kim

    Bora Yeon, Ah Young Suh, Eunmi Choi and Bonggi Kim. Pharmacoepidemiology and Risk Management 2025;17:81-98. https://doi.org/10.56142/perm.25.0010


  • Open Access

    Risk of Osteoporosis Associated with HMG-CoA Reductase Inhibitors in Patients with Dyslipidemia: A Retrospective Cohort Study in Korea

    by Hyeri Yang, Dayoung Shim, Eunmi Choi, Myungsik Yoo, Bonggi Kim

    Hyeri Yang, Dayoung Shim, Eunmi Choi, Myungsik Yoo and Bonggi Kim. Pharmacoepidemiology and Risk Management 2024;16:135-45. https://doi.org/10.56142/perm.24.0012

  • Open Access

    Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea

    by Hyunjoo Kim, Nayeong Son, Dahee Jeong, Myungsik Yoo, In Young Choi, Wona Choi, Yeon Woong Chung, Sung Woo Ko, Seonjeong Byun, Sun Im, et al.

    Introduction Angiotensin receptor blockers are widely used antihypertensive drugs in South Korea. In 2021, the Korea Ministry of Food and Drug Safety acknowledged the need for national compensation for a drug-induced liver injury (DILI) after azilsartan use. However, little is known regarding the association between angiotensin receptor blockers and DILI. Objective We conducted a retrospective cohort study in incident users of angiotensin receptor blockers from a common data model database (1 January, 2017–31 December, 2021) to compare the risk of DILI among specific angiotensin receptor blockers against valsartan. Methods Patients were assigned to treatment groups at cohort entry based on prescribed angiotensin receptor blockers. Drug-induced liver injury was operationally defined using the International DILI Expert Working Group criteria. Cox regression analyses were conducted to derive hazard ratios and the inverse probability of treatment weighting method was applied. All analyses were performed using R. Results In total, 229,881 angiotensin receptor blocker users from 20 university hospitals were included. Crude DILI incidence ranged from 15.6 to 82.8 per 1000 person-years in treatment groups, most were cholestatic and of mild severity. Overall, the risk of DILI was significantly lower in olmesartan users than in valsartan users (hazard ratio: 0.73 [95% confidence interval 0.55–0.96]). In monotherapy patients, the risk was significantly higher in azilsartan users than in valsartan users (hazard ratio: 6.55 [95% confidence interval 5.28–8.12]). Conclusions We found a significantly higher risk of suspected DILI in patients receiving azilsartan monotherapy compared with valsartan monotherapy. Our findings emphasize the utility of real-world evidence in advancing our understanding of adverse drug reactions in clinical practice.


  • Open Access

    Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer

    by Soyoung Kang, Bora Yeon, Myo-Song Kim, Myungsik Yoo, Bonggi Kim, Yun Mi Yu

    Importance: The association of tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFR-TKIs) with aneurysm and artery dissection (AAD) has been frequently reported in spontaneous reporting databases.Objective: To investigate the risk and incidence of AAD occurrence in patients with cancer treated with oral VEGFR-TKIs, with capecitabine as an active comparator.Design, Setting, and Participants: This national, historical cohort study was conducted using national claims data from the National Health Insurance Service in Korea from 2007 to 2020, with a 1-year follow-up. Patients with cancer aged 40 years or older prescribed oral VEGFR-TKIs or capecitabine were enrolled. Data were analyzed from September 2022 through April 2023.Exposure: Oral VEGFR-TKIs (sorafenib, regorafenib, vandetanib, sunitinib, lenvatinib, axitinib, and pazopanib) or capecitabine as a comparator.Main Outcomes and Measures: Hazard ratios (HRs) were used to investigate the association between VEGFR-TKI use and AAD after propensity score matching. The primary outcome was AAD, and secondary outcomes were aortic aneurysm and dissection and AAD with rupture. Outcomes were defined using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis codes.Results: Among 127 710 patients with cancer eligible for the study (80 386 males [62.9%]; mean [SD] age, 62.6 [10.9] years), 37 308 patients received VEGFR-TKIs and 90 402 patients received capecitabine. Among 27 535 matched patients receiving VEGFR-TKIs, the incidence of AAD within 1 year of treatment initiation was 6.0 per 1000 person-years. The median (IQR) time to AAD onset in the matched AAD group was 114 (67-257) days after treatment initiation, with the highest incidence observed during the first 3 months (45 incidents vs 31, 17, and 16 incidents during 3- to 6-month, 6- to 9-month, and 9- to 12-month periods, respectively). Cox regression modeling showed that the risk of AAD occurrence was significantly higher among patients prescribed VEGFR-TKIs than those receiving capecitabine (HR, 1.48; 95% CI, 1.08-2.02); similar results were obtained among females (HR, 2.08; 95% CI, 1.26-3.42), older adults (aged ≥65 years; HR, 1.42; 95% CI, 1.01-1.99), and patients with dyslipidemia (HR, 1.58; 95% CI, 1.11-2.24).Conclusions and Relevance: In this study, the use of oral VEGFR-TKIs was associated with an increased risk of AAD occurrence. These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use.


  • Open Access

    `Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea

    by Hoon Jeong, Eunmi Choi, Ahyoung Suh, Myungsik Yoo, Bonggi Kim

    Febuxostat is the drug used to treat hyperuricemia in patients with gout. Recently, the usage of Febuxostat has been controversial over the side effects in cardiovascular. The study aimed to comparatively analyze the risk of cardiovascular disease associated with febuxostat and allopurinol use in Korean patients with gout. A cohort study was conducted using national insurance claim data from the Health Insurance Review and Assessment Service (HIRA). Adult patients who were diagnosed with gout and prescribed febuxostat or allopurinol more than once from July 1, 2015, to June 30, 2018 were studied. The outcome was cardiovascular disease. Analysis was performed using Cox’s proportional hazard model following 1:1 propensity score matching to estimate the hazard ratio with a 95% confidence interval. In total, 90,590 patients were defined as the final study cohort who had an average follow-up of 467 days, including 28,732 and 61,858 patients in the febuxostat and allopurinol groups, respectively. After the 1:1 propensity score matching, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.17; 95% CI: 1.10–1.24). In the sensitivity analysis, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.09; 95% CI: 1.04–1.15). However, further sensitivity analysis showed no statistically significant difference between the febuxostat group and allopurinol group after adjusting for cardiovascular disease history before the index date. Similarly, no statistically significant difference was found between the two drugs in the subgroup analysis. Febuxostat was not associated with a significantly increased risk of cardiovascular disease.


  • Open Access

    Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea

    by Bora Yeon, Ah Young Suh, Eunmi Choi, Bonggi Kim, Eunsun Noh, Soo Youn Chung, Soon Young Han

    Background: One of the most prescribed treatments for benign prostatic hyperplasia (BPH) is 5α-reductase inhibitors (5ARI). Europe experienced recent safety issues involving 5ARI and depression symptoms, with similar findings being seen in Western countries. The South Korea has updated the drug label in accordance with European recommendations, but the relevant evidence was insufficient. This study compared the use of 5ARI versus α-blocker (AB) as a treatment for BPH and related risks of depression to provide evidence based on the Korean population. Methods: This was a retrospective cohort study using South Korea’s Health Insurance Review & Assessment Service claim data from 2011 to 2017. New patients diagnosed in men with BPH and taking medications that contained either 5ARI or AB between July 1, 2013, and June 30, 2015, were included (n = 1,461 5ARI; n = 18,650 AB). The primary outcome was depression defined per the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10: F32-34, F38, F412, F432). Logistic regression was used to implement 1:1 propensity score (PS) matching of patients taking 5ARI to those taking AB to adjust for confounding. Cox proportional hazard models were used to compare the risk of depression associated with 5ARI versus AB. Results: Balance in baseline characteristics between the treatment groups were achieved within PS matched pairs (1,461 pairs). Compared to the AB medication group, the 5ARI group had lower depression (HR: 0.69, 95% CI: [0.51–0.92]). However, we could not find a clinically relevant, statistical difference after PS matching (HR: 0.91, 95% CI: [0.61–1.36]). Conclusions: The risk of depression associated with 5ARI was not meaningfully different from AB in Korea, which suggests that medical officials should provide the most appropriate medication for BPH patients by considering both treatment benefits and depression risk.